ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Cyclically Adjusted Revenue per Share: kr6.67 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:EXPRS2 ExpreS2ion Biotech Holding AB OSTO:EXPRS2
43 GF Score
Price kr1.40
GF Value kr3.43
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is ExpreS2ion Biotech Holding AB Cyclically Adjusted Revenue per Share?

ExpreS2ion Biotech Holding AB OSTO:EXPRS2 -2.78% 43 Cyclically Adjusted Revenue per Share is kr6.67 as of Mar. 2026. GuruFocus rates OSTO:EXPRS2 with a GF Score™ of 43/100 and a GF Value™ of kr3.43 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ExpreS2ion Biotech Holding AB's adjusted revenue per share for the three months ended in Mar. 2026 was kr0.008. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr6.67 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-16), ExpreS2ion Biotech Holding AB's current stock price is kr1.40. ExpreS2ion Biotech Holding AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr6.67. ExpreS2ion Biotech Holding AB's Cyclically Adjusted PS Ratio of today is 0.21.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ExpreS2ion Biotech Holding AB was 1.39. The lowest was 0.21. And the median was 0.82.


ExpreS2ion Biotech Holding AB  (OSTO:EXPRS2) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ExpreS2ion Biotech Holding AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=1.40/6.67
=0.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ExpreS2ion Biotech Holding AB was 1.39. The lowest was 0.21. And the median was 0.82.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ExpreS2ion Biotech Holding AB Cyclically Adjusted Revenue per Share Related Terms


ExpreS2ion Biotech Holding AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ExpreS2ion Biotech Holding AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ExpreS2ion Biotech Holding AB Cyclically Adjusted Revenue per Share Chart

ExpreS2ion Biotech Holding AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 6.83

ExpreS2ion Biotech Holding AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 7.20 7.01 6.83 6.67

OSTO:EXPRS2 vs VRTX, REGN, ALNY: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, ExpreS2ion Biotech Holding AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ExpreS2ion Biotech Holding AB Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ExpreS2ion Biotech Holding AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ExpreS2ion Biotech Holding AB's Cyclically Adjusted PS Ratio falls into.


OSTO:EXPRS2
43GF Score
ExpreS2ion Biotech Holding AB OSTO:EXPRS2
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ExpreS2ion Biotech Holding AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ExpreS2ion Biotech Holding AB's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.008/133.5600*133.5600
=0.008

Current CPI (Mar. 2026) = 133.5600.

ExpreS2ion Biotech Holding AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201603 7.832 100.751 10.382
201609 1.767 101.138 2.333
201612 2.643 102.022 3.460
201703 4.217 102.022 5.521
201706 2.616 102.752 3.400
201709 2.276 103.279 2.943
201712 1.832 103.793 2.357
201803 2.255 103.962 2.897
201806 2.502 104.875 3.186
201809 1.796 105.679 2.270
201812 1.190 105.912 1.501
201903 2.247 105.886 2.834
201906 3.228 106.742 4.039
201909 2.539 107.214 3.163
201912 1.078 107.766 1.336
202003 1.690 106.563 2.118
202006 1.058 107.498 1.315
202009 0.460 107.635 0.571
202012 0.309 108.296 0.381
202103 0.657 108.360 0.810
202106 1.837 108.928 2.252
202109 0.987 110.338 1.195
202112 1.173 112.486 1.393
202203 0.790 114.825 0.919
202206 0.448 118.384 0.505
202209 0.272 122.296 0.297
202212 0.293 126.365 0.310
202303 0.790 127.042 0.831
202306 0.571 129.407 0.589
202309 0.405 130.224 0.415
202312 0.286 131.912 0.290
202403 0.238 132.205 0.240
202406 0.121 132.716 0.122
202409 0.044 132.304 0.044
202412 0.068 132.987 0.068
202503 0.133 132.825 0.134
202506 0.154 133.699 0.154
202509 0.035 133.480 0.035
202512 0.044 133.390 0.044
202603 0.008 133.560 0.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr6.67 mean?
ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) has a Cyclically Adjusted Revenue per Share of kr6.67 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ExpreS2ion Biotech Holding AB and its competitors.
Is ExpreS2ion Biotech Holding AB's Cyclically Adjusted Revenue per Share too high?
ExpreS2ion Biotech Holding AB's current Cyclically Adjusted Revenue per Share is kr6.67. Overall, ExpreS2ion Biotech Holding AB has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ExpreS2ion Biotech Holding AB's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
ExpreS2ion Biotech Holding AB's Cyclically Adjusted Revenue per Share of kr6.67 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ExpreS2ion Biotech Holding AB and its competitors. ExpreS2ion Biotech Holding AB's current Cyclically Adjusted Revenue per Share is kr6.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ExpreS2ion Biotech Holding AB stock overvalued right now?
Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) is currently considered Possible Value Trap. The stock's GF Value™ is kr3.43, compared to a current price of kr1.40 — trading 59.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr6.67. ExpreS2ion Biotech Holding AB's overall GF Score™ is 43/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ExpreS2ion Biotech Holding AB (OSTO:EXPRS2), the current Cyclically Adjusted Revenue per Share is kr6.67 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ExpreS2ion Biotech Holding AB (OSTO:EXPRS2) Overvalued in 2026?

Based on GuruFocus' analysis, ExpreS2ion Biotech Holding AB stock appears to be undervalued. The current stock price of kr1.40 is trading 59.2% below its estimated GF Value™ of kr3.43. GuruFocus considers ExpreS2ion Biotech Holding AB to be Possible Value Trap.

Key valuation signals for OSTO:EXPRS2:

  • Cyclically Adjusted Revenue per Share: kr6.67
  • GF Value™: kr3.43 vs. price of kr1.40 (59.2% below fair value)
  • GF Score™: 43/100 with 5 warning signs

No single metric tells the full story. See the OSTO:EXPRS2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ExpreS2ion Biotech Holding AB Business Description

Other Exchanges 5JD0:Germany
Address c/o Mindpark, Ronnowsgatan 8c, Helsingborg, SWE, 252 25
ExpreS2ion Biotech Holding AB is a biotechnology company that develops vaccines. It has developed a human clinical Phase III-validated technology platform, ExpreS2, for fast and efficient development and production of the active material in vaccines. The platform, under the brand GlycoX-S2, includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Its product pipeline comprises ES2B-C001, a HER2-VLP-based vaccine in development for human breast cancer therapy and several exploratory vaccine projects targeting pathways validated by commercial monoclonal antibody products. Geographically, the company operates in the Nordics region and also has a presence in other countries.
43GF Score

Get the complete analysis for OSTO:EXPRS2

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1.40
Price
kr3.43
GF Value